CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


25-OH cholecalciferolWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (5)


Name (Synonyms) Correlation
drug2123 SAMBA II (Diagnostic for the Real World) Wiki 1.00
drug510 Cambridge Validated Viral Detection Method Wiki 1.00
drug2720 Zinc gluconate Wiki 1.00
drug2019 Radiological Detection Wiki 1.00
drug1944 Public Health England Gold Standard Wiki 1.00

Correlated MeSH Terms (3)


Name (Synonyms) Correlation
D000208 Acute Disease NIH 0.71
D014777 Virus Diseases NIH 0.12
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Impact of Zinc and Vitamin D3 Supplementation on the Survival of Institutionalized Aged Patients Infected With COVID-19

Mortality from Covid-19 increases with age, reaching 14.8% from the age of 80. The severity of the infection is linked to the acute respiratory distress syndrome (ARDS) which requires intensive care. ARDS is the consequence of the reactional inflammatory storm that damages the lungs. Aged subjects are particularly prone to zinc and vitamin D deficiency. These two micronutrients are able to modulate the immune response by reducing the inflammatory storm. The hypothesis is that supplementation with zinc and vitamin D would reduce the inflammatory reaction which worsens ARDS and leads to the death of subjects infected with Covid-19.

NCT04351490 SARS-CoV 2 Dietary Supplement: Zinc gluconate Dietary Supplement: 25-OH cholecalciferol

Primary Outcomes

Measure: Survival rate in asymptomatic subjects at inclusion

Time: Two months after inclusion

Secondary Outcomes

Measure: Survival rate in symptomatic subjects at inclusion

Time: Two months after inclusion

Description: symptomatic subjects and asymptomatic subjects

Measure: Survival rate in overall subjects

Time: Two months after inclusion

Measure: Cumulative incidence of Covid-19 infection in asymptomatic subjects at inclusion

Time: Within two months after inclusion


No related HPO nodes (Using clinical trials)